The Annals Visit the journal of Pharmacy Technology for more pharmacy practice research and reviews!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 22 June 2004, www.theannals.com, DOI 10.1345/aph.1D589.
 The Annals of Pharmacotherapy: Vol. 38, No. 9, pp. 1520-1524. DOI 10.1345/aph.1D589
© 2004 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carr, R. R
Right arrow Articles by Nahata, M. C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carr, R. R
Right arrow Articles by Nahata, M. C

DRUG INFORMATION ROUNDS

Azithromycin for Improving Pulmonary Function in Cystic Fibrosis

Roxane R Carr, PharmD

Pediatric Pharmacotherapy Fellow, College of Pharmacy, Ohio State University, Columbus, OH

Milap C Nahata, PharmD

Professor of Pharmacy and Division Chair, College of Pharmacy; Professor of Pediatrics and Internal Medicine, College of Medicine and Public Health, Ohio State University and Children's Hospital, Columbus

Reprints: Milap C Nahata PharmD, College of Pharmacy, Ohio State University, 500 W. 12th Ave., Columbus, OH 43210-1291, fax 614/292-1335.

OBJECTIVE: To review the literature concerning the use of azithromycin in the treatment of patients with cystic fibrosis (CF).

DATA SOURCES: A search of MEDLINE (1966–April 2004), Embase (1980–April 2004), and International Pharmaceutical Abstracts (1971–April 2004) was performed. Search terms included cystic fibrosis, macrolide, and azithromycin.

DATA SYNTHESIS: Four studies have been performed in 7–185 patients (children and adults) over a 3- to 6-month period. The azithromycin dosage ranged from 250 mg 3 times weekly to 500 mg daily. The trials reported an improvement in percent predicted forced expiratory volume ranging from 2.95% to 6.2% in patients treated with azithromycin compared with those receiving placebo.

CONCLUSIONS: Azithromycin appeared to improve pulmonary function in adults and older children with CF and was well tolerated when administered for 6 months. Further research is needed to determine an optimal dosage regimen, duration of treatment, effects on quality of life, and cost-effectiveness of azithromycin therapy.

Key Words: adults, azithromycin, children, cystic fibrosis

Published Online, June 22, 2004. www.theannals.com, DOI 10.1345/aph.1D589


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
Y. Nalca, L. Jansch, F. Bredenbruch, R. Geffers, J. Buer, and S. Haussler
Quorum-Sensing Antagonistic Activities of Azithromycin in Pseudomonas aeruginosa PAO1: a Global Approach.
Antimicrob. Agents Chemother., May 1, 2006; 50(5): 1680 - 1688.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2004 by Harvey Whitney Books Company.